Research and Markets (http://www.researchandmarkets.com/research/8rkp5k/brintellix_major)
has announced the addition of the "Brintellix
(Major Depressive Disorder) - Forecast and Market Analysis to 2023"
report to their offering.
Brintellix (vortioxetine) is a multimodal antidepressant that is
indicated for the treatment of MDD and was co-developed by Lundbeck and
Takeda. It gained FDA approval in October 2013 and EMA approval in
December 2013. Brintellix launched in the US market in January 2014 and
its launch in European markets is expected during the second half of
2014 (Lundbeck, press release, December 27, 2013).
Overview of Major depressive disorder, including epidemiology,
etiology, symptoms, diagnosis, pathology and treatment guidelines as
well as an overview on the competitive landscape.
Detailed information on Brintellix including product description,
safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for Brintellix for the top eight countries from 2013 to
Sales information covered for the US, France, Germany, Italy, Spain,
the UK, Japan and Australia.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Brintellix (Vortioxetine)
For more information visit http://www.researchandmarkets.com/research/8rkp5k/brintellix_major
Copyright Business Wire 2014